![]() “Day One was founded to solve a critical unmet need: Children are being left behind during a cancer treatment revolution,” said Jeremy Bender, Ph.D., chief executive officer of Day One. Food and Drug Administration (FDA) for the treatment of pediatric patients with low-grade glioma harboring an activating RAF alteration who have progressed after one or more prior systemic therapies. DAY101 has been granted Breakthrough Therapy designation by the U.S. In addition, Day One plans to initiate an adult solid tumor study to further evaluate DAY101 in patients with RAF-altered tumors for which there are no currently approved therapies. The Company has initiated the pivotal Phase 2 FIREFLY-1 study with DAY101 in pediatric low-grade glioma (pLGG), which is the most common form of childhood brain cancer and has no approved therapies. With the completion of the Series B financing, Day One has raised more than $190 million from leading life science investors since the Company initiated operations in late 2019.ĭAY101 is designed as a first-in-class, oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor. Proceeds from the Series B financing will allow Day One to accelerate and expand its search and evaluation capabilities, support drug development efforts and continue advancing commercial launch plans for the Company’s lead program, DAY101. Existing investors Canaan, Access Biotechnology, and Atlas Venture also participated.ĭay One is a purpose-built company passionately committed to advancing important new cancer treatments for patients of all ages, with a focus on children. Rowe Price Associates, Inc., and Viking Global Investors. The financing was led by RA Capital Management with participation from additional new investors Boxer Capital, BVF Partners L.P., Franklin Templeton, Janus Henderson Investors, Perceptive Advisors, funds and accounts advised by T. ![]() ![]() SAN FRANCISCO-( BUSINESS WIRE)-Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced a $130 million Series B financing from leading life sciences investors. ![]()
0 Comments
Leave a Reply. |